Digital Twins Help Bioreactors to Produce Personalized, Cell-Based Therapies

Digital Twins Help Bioreactors to Produce Personalized, Cell-Based Therapies

While a few big pharma companies produced amazing results in developing and manufacturing massive amounts of COVID-19 vaccines in under a year, many pharma challenges exist on a smaller scale — that of an individual patient or small group of patients with a rare disease. This “personalized medicine” approach has led companies like Antleron in Leuven, Belgium, to redefine the concept of a bioreactor, using Ansys simulation solutions and digital twins to optimize and customize the growth of cells for therapeutic purposes.


Whitepaper

Complete the form below to download the content.

* - marks a required field

Answer the following questions about your organization below:


Company

© 2023 TheEnterpriseGuide. All rights reserved.